RT/CART-19 combination treatment enhances crosspresentation of TAAs and T-cell responses to TAAs. (A) CD45.2⁺/CD11c⁺ DC infiltration in irradiated tumor on day 23 and day 34 after tumor challenge. (B-C) AH1-specific T-cell infiltration in irradiated and abscopal tumors on day 23 and day 34 after tumor challenge. (D) IFN-γ spots of an enzyme-linked immunospot (ELISPOT) assay after stimulation of tumor cell suspensions with AH1 peptide. (E) CD45.2⁺/CD3⁺ T cells isolated from treated mice stimulated with AH1 peptide and incubated with A20 tumor cells. (F) CD45.2⁺/CD3⁺ T cells isolated from treated mice stimulated with AH1 peptide and incubated with CT26 tumor cells. Graphs show the mean ± SEM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. CTR, control.